metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-3 PIRFENIDONE PREVENTS OBESITY-ASSOCIATED NONALCOHOLIC STEATOHEPATITIS AND CAR...
Journal Information
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Full text access
P-3 PIRFENIDONE PREVENTS OBESITY-ASSOCIATED NONALCOHOLIC STEATOHEPATITIS AND CARDIAC FIBROSIS THROUGH HORMONAL REPROGRAMMING
Visits
223
Jorge Gutiérrez, Daniel López, Ana Soledad Sandoval, Ángel Omar Vázquez, Jonathan Samael Rodríguez, Juan Armendáriz
Department of Molecular Biology and Genomics, CUCS, Institute for Molecular Biology in Medicine and Gene Therapy, University of Guadalajara, Guadalajara, México
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S1

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Introduction and Objectives

Obesity is now a worldwide epidemic, associated with insulin resistance, nonalcoholic steatohepatitis (NASH), and cardiovascular diseases (CVDs), being the latter main cause of global death. NASH is common among Hispanics, characterized by fatty infiltration, inflammation, with or without hepatic fibrosis, and shows hormonal dysregulation. Pirfenidone (PFD) is an anti-inflammatory, and anti-fibrotic drug. Previously, we reported that PFD has anti-steatosis effects on hepatic and cardiac tissues in mice with NASH, but its mechanisms involved are not completely known. The aim of this study was to investigate the effects of PFD on hormonal regulation in high-fat/high-carbohydrate (HFHC)- diet-induced obese male C57BL/6J mice.

Materials and Methods

At the age of 19-20 weeks, mice were fed with normal diet (ND, 6.2% lipids, 44.2 carbohydrates, 18.6% proteins, n=7) and normal water. Other mice were fed with HFHC (60.3% lipids, 21.4% carbohydrates, 18.3% proteins, n=14) and water with carbohydrates (2.31% fructose and 1.89% sucrose) diet for 16 weeks; at 8 weeks of feeding, seven mice with HFHC diet were administered PFD (300 mg/kg/day) by gavage. Experiments were performed according to the ARRIVE guidelines. Insulin tolerance test (4 h of fasting), ELISA, Hematoxylin-Eosin and Masson staining, and morphometric analysis were performed. Data analysis were evaluated using one-way ANOVA with Tukey post hoc test.

Results

HFHC mice showed NASH with an increase in resistin and aspartate aminotransferase (P0.05). Parameters significantly elevated in HFHC were prevented by PFD such as weight (body, liver, and heart), tibia length, epididymal fat, hepatic steatosis, insulin resistance, hormones (insulin, glucagon, leptin, plasminogen activator inhibitor 1) (Table), triglycerides, total cholesterol, LDL, and VLDL, including inflammatory foci and fibrosis in hepatic and cardiac tissue (P0.05). PFD decreased alanine aminotransferase (P0.05).

Conclusions

PFD decreases metabolic hormones and could be a promising drug for the prevention of obesity-induced NASH and CVDs.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos